3 New Strong Buy Ratings from Top-Rated Analysts: 10/21/2025
Here is the latest and greatest from our most popular screener:
- Shoals Technologies Group (SHLS) is a top-rated solar stock with multiple upcoming catalysts
- Primoris Services (PRIM) is a repeat pick — find out why it’s back on the list
- Mirum Pharmaceuticals (MIRM) could be a near-term growth machine
P.S. Want more great stock picks? Consider subscribing to Zen Investor.
A note from our sponsors...
Sell Nvidia and replace it with WHAT?! The AI trade is running full throttle. But it won't last forever. It's not time to abandon AI stocks completely, but it IS time to prepare for the inevitable slowdown. Futurist Eric is giving away 7 free trade ideas in his "Sell This, Buy That" research package, where he reveals which market moves you need to make today (starting with getting rid of Nvidia stock.) Access these trade ideas here.1. Shoals Technologies Group Inc (NASDAQ: SHLS)
Shoals Technologies specializes in utility-scale solar installations and is positioned to benefit from increasing U.S. infrastructure and clean energy spend. Upcoming Q3 2025 results (Nov 4) could signal inflections as tariff and safe harbor volumes begin to shape order flows.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $9.95 — get current quote >
Max 1-year forecast: $11.00
Why we're watching:
- Analyst support: Currently, SHLS has 7 Strong Buy ratings as well as 1 Buy, 1 Hold, and 1 Sell. See the ratings
- Notably, Morgan Stanley researcher Andrew Percoco (top 10%) anticipates “safe harbor volumes and orders” will begin flowing into both residential and utility-scale U.S. solar manufacturers, flagging Q3 as a catalyst.
- Shoals is up over 100% year-over-year;rRevenue and earnings growth are projected at 15.7% and 73% respectively over the next year.
- As a B-rated stock according to Zen Ratings, SHLS is in a class of stocks that have delivered 19.88% annualized returns.
- Digging into the Component Grades, SHLS is in the upper quartile for both Growth and Financials. See all 7 Zen Component Grades here >
2. Primoris Services Corp (NYSE: PRIM)
It’s back on the list! Primoris Services serves energy, utilities, and civil infrastructure customers. A strong backlog, robust U.S. manufacturing tailwinds, and a focus on long-term cash flow visibility have propelled this specialty contractor to new highs.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $138.50 — get current quote >
Max 1-year forecast: $170.00
Why we're watching:
- Analyst support: PRIM currently has strong bullish sentiment: 11 Strong Buy ratings, and just 1 Hold rating. See the ratings
- For example, JP Morgan researcher Mark Strouse (top 5%) just hiked his price target, citing PRIM’s strategic positioning in clean energy and U.S.-linked manufacturing, and predicts utility-scale solution providers remain best-positioned going into the next year.
- PRIM’s 1- and 3-year returns (+119% and +56.6%) outpace most sector peers, and the company posts strong cash flow (operating cash flow of $665M) with a solid Value (C) and Growth (A) profile.
- Industry ranking context: PRIM is #8 out of 45 stocks in the high-performing Engineering & Construction industry (Industry Rating: A).
- PRIM has an above-average Zen Rating of B, and shows particular strength in its Component Grades for Growth (A — excellent), as well as for Safety, Momentum, and Financials (all Bs, or above average). See all 7 Zen Component Grades here >
3. Mirum Pharmaceuticals Inc (NASDAQ: MIRM)
Speculators, take note! This biotech develops and commercializes novel therapies for rare and orphan liver diseases. Investor focus is on the late-stage pipeline, with Phase 2b data for volixibat expected to drive the “next wave of growth” in 2026.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $73.53 — get current quote >
Max 1-year forecast: $95.00
Why we're watching:
- Analyst support: Analysts are resoundingly bullish: MIRM has 5 Strong Buy and 3 Buy ratings, with no Hold, Sell, or Strong Sells. See the ratings
- For example, Morgan Stanley researcher Michael Ulz (top 10%) emphasized the upcoming Phase 2b study milestones and sees these as pivotal for Mirum’s growth trajectory.
- Currently, MIRM ranks as the 7th highest-rated among 481 Biotech stocks.
- With a Zen Rating of A, MIRM is in an elite class of stocks that have historically averaged 32.52% annual returns.
- Digging into the Component Grades, MIRM shows particular strength in several key areas: Growth (A — top-tier percentile) and Momentum, Sentiment, and from our proprietary AI factor (all Bs). See all 7 Zen Component Grades here >
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.